title: Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results.
abstract: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor AML leaves room for substantial improvement. We discuss treatments that have improved outcome in this group of patients with AML and ongoing/future strategies that might contribute toward incremental gains.
  
  
  BACKGROUND
  Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement.
  
  
  METHODS
  We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts.
  
  
  RESULTS
  Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer.
  
  
  CONCLUSIONS
  Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.
authors.affiliation: Leukemia Department, MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Vijaya Raj
authors.initials: VR
authors.lastname: Bhatt
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.forename: Jorge E
authors.initials: JE
authors.lastname: Cortes
authors.forename: Farhad
authors.initials: F
authors.lastname: Ravandi
authors.forename: Gautam
authors.initials: G
authors.lastname: Borthakur
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D007446:Chromosome Inversion; D050660:Core Binding Factors / Q000235:genetics*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000401:mortality / Q000628:therapy*; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D011379:Prognosis; D014178:Translocation, Genetic; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D050660:Core Binding Factors; D015514:Oncogene Proteins, Fusion